Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339634 · ClinicalTrials.gov registry record
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
A clinical trial, sponsored by Tabula Rasa HealthCare.
- Completed
- Registry status
- 12,873
- Enrollment target
NCT04339634: Completed study, sponsored by Tabula Rasa HealthCare.
NCT04339634 is a clinical trial that has completed, run by Tabula Rasa HealthCare. The registered enrollment target is 12,873 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04339634 has completed, sponsored by Tabula Rasa HealthCare.
- COMPLETED
- Registry status
- 12,873 participants
- Enrollment target
Study Summary
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.
Primary Outcome
Quantitative
Interventions
- OTHER Simulation of Repurposed Drugs for COVID-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,873 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2023-01-30 |
What the finished NCT04339634 record still lists
NCT04339634 is an observational study that tracks outcomes without assigning an intervention. Its 12,873 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Simulation of Repurposed Drugs for COVID-19 is the first listed.
NCT04339634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04339634 about?
NCT04339634 is a clinical study titled "Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy". This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify pote...
What is the current status of trial NCT04339634?
This trial is currently completed. The enrollment target is 12,873 participants. The study started on 2020-04-02. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04339634?
The interventions under investigation include: Simulation of Repurposed Drugs for COVID-19 (OTHER).
Who is sponsoring clinical trial NCT04339634?
This trial is sponsored by Tabula Rasa HealthCare, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI